Summary
Signal counts
Assets tracked: 4
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
City of Hope Medical Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03346135 | https://clinicaltrials.gov/study/NCT04532372 | https://clinicaltrials.gov/study/NCT04565665 | https://clinicaltrials.gov/study/NCT07087860 | https://clinicaltrials.gov/study/NCT03712202 | https://clinicaltrials.gov/study/NCT04929392 | https://clinicaltrials.gov/study/NCT00005976 | https://clinicaltrials.gov/study/NCT05952453 | https://clinicaltrials.gov/study/NCT03442556 | https://clinicaltrials.gov/study/NCT00303849
Assets
Linked programs
- Autologous Hematopoietic Stem Cell Transplantation: Low Signal (1/5)
- Best Practice: Low Signal (1/5)
- Bleomycin: Timeline Staleness Signal (3/5)
- Carboplatin: Registry Stop Signal (5/5)